Objective To compare the efficacy and safety of venlafaxine and paroxetine in the treatment of comorbidity of depressionwith anxiety disorder. Methods 86 cases simultaneously conformed to depression and anxiety disorder accepted venlafaxine (group A) orparoxetine (group B) for 8 weeks. They were assessed with Hamilton Rating Scale for Depression (HAMD) and Hamilton Rating Scale forAnxiety (HAMA) before and 1, 2, 8 weeks after treatment. Results There was no significant difference in the scores of HAMD and HAMAbetween both groups before treatment, and there was since 1 week after treatment (P<0.05). 45.4% were clinically cured and 75.0% improvedin group A, which was 33.3% and 66.6% in group B 8 weeks after treatment (P<0.05). Conclusion Venlafaxine is more efficaciousthan paroxetine on anxiety and depression comorbidity.

Objective To explore the depression and its related factors of the patients with craniocerebral injury during rehabilitation.Methods 111 patients with craniocerebral injury were investigated with the questionnaire about general condition. They were assessed withHamilton Rating Scale for Depression (HAMD). The relationship between the general condition and the score of HAMD were analyzed. ResultsThere were 27 cases (24.32%) with score of HAMD≤7, 31 cases (27.93%) with the score from 8 to 17 and 53 cases (47.75%) with thescore≥18. The score of HAMD was significantly related to the patients' age, education, profession, economy status, economic compensationand the cause of injury (P<0.05). However, it was not related to the sexuality, marital status, registered residence, level of the injury, thecourse of disease and the coma time (P>0.05). Only economy state (x₁), education (x₂) and economic compensation (x₃) entered into the regressionequation by multiple regression analysis: y=22.782-6.879x₁+2.357x₂+3.54x₃ (F=75.609, P=0.000). Conclusion Patients with craniocerebralinjury generally depress during rehabilitation. The patients with a worse economy state, a higher education and no economic compensationappear more serious depression.

Objective:To explore the efficacy and safety of amisulpiride at low dosage combined with clozapine in the treatment of refractory schizophrenia. Methods:Totally 160 patients with refractory schizophrenia were chosen from the psychiatric department of 4 hospitals during January to September in 2014 and randomly divided into the observation group and the control group with 80 cases in each. The patients were treated with clozapine plus amisupiride or clozapine plus placebo for 12 weeks. The positive and negative syn-drome scale ( PANSS) and treatment emergent side effect scale ( TESS) was used to respectively evaluate the efficacy and the adverse effects. Results:At the weekend of the 4th, 8th and 12th week after the treatment, the clinical efficacy in the observation group was sig-nificantly better than that in the control group (all P<0. 05). The total and every factors scores of PANSS after the treatment were sig-nificantly lower than those before the treatment in both groups ( P<0. 01), and the decrease in the observation group was more signifi-cant than that in the control group (P<0. 05 or P<0. 01). There was no significant difference in the incidence of adverse effects be-tween the two groups (P>0. 05). Conclusion:Amisulpiride at low dosage combined with clozapine can significantly improve the effi-cacy in the treatment of refractory schizophrenia without added adverse effects.